This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Acuña, L. R. Articles by Leone, B. Search for Related Content PubMed PubMed Citation Articles by Acuña, L. R. Articles by Leone, B.

Vinorelbine and Paclitaxel as First-Line Chemotherapy in Metastatic Breast Cancer

From the Grupo Oncológico Cooperativo del Sur, Argentina.

Address reprint requests to Dr Luis Romero Acuña, GOCS Neuquén, Rivadavia 360, 8300 Neuquén, Argentina

PURPOSE: To evaluate the efficacy and toxicity of a combination of vinorelbine (VNB) and paclitaxel (PTX) as first-line chemotherapy in metastatic breast carcinoma (MBC).

PATIENTS AND METHODS: Between August 1995 and August 1997, 49 patients with untreated MBC received a regimen that consisted of VNB 30 mg/m² in a 20-minute intravenous (IV) infusion on days 1 and 8 and PTX 135 mg/m² in a 3-hour IV infusion (starting 1 hour after VNB) on day 1. Cycles were repeated every 28 days. The median age of the patients was 52 years, and 59% of patients were postmenopausal. Median performance status was 1. Dominant sites of disease were soft tissue in 6%, bone in 29%, and viscera in 65%.

RESULTS: Objective responses were recorded in 27 of 45 assessable patients (60%; 95% confidence interval, 46% to 74%). Complete remissions occurred in three patients (7%), and partial remissions occurred in 24 patients (53%). No change was recorded in 12 patients (27%), and progressive disease occurred in six patients (13%). The median time to treatment failure was 7 months, and median survival duration was 17 months. The limiting toxicity was myelosuppression, mainly leukopenia in 49 patients (100%) (grade 1 to grade 2, four patients; grade 3, 30 patients; and grade 4, 15 patients). Neutropenia was observed in 100% of patients (grade 1 to grade 2, three patients; grade 3, 11 patients; grade 4, 35 patients). Two treatment-related deaths due to febrile neutropenia were observed in patients with massive liver involvement. Peripheral neurotoxicity developed in 33 patients (67%) (grade 1, 25 patients; grade 2, eight patients); there were no grade 3 or grade 4 episodes.

CONCLUSION: The combination of VNB-PTX showed significant activity as first-line chemotherapy for patients with MBC. Myelosuppression was the dose-limiting side effect, whereas neurotoxicity was mild to moderate.

This article has been cited by other articles:

				M. Toi, T. Saeki, K. Aogi, M. Sano, K. Hatake, T. Asaga, Y. Tokuda, S. Mitsuyama, M. Kimura, T. Kobayashi, et al. Late Phase II Clinical Study of Vinorelbine Monotherapy in Advanced or Recurrent Breast Cancer Previously Treated with Anthracyclines and Taxanes Jpn. J. Clin. Oncol., June 1, 2005; 35(6): 310 - 315. [Abstract] [Full Text] [PDF]

				G. Freyer, T. Delozier, M. Lichinister, D. Gedouin, P. Bougnoux, P. His, K. Imadalou, and V. Trillet-Lenoir Phase II Study of Oral Vinorelbine in First-Line Advanced Breast Cancer Chemotherapy J. Clin. Oncol., January 1, 2003; 21(1): 35 - 40. [Abstract] [Full Text] [PDF]

				G. Mustacchi, M. Muggia, S. Milani, R. Ceccherini, M. L. Leita, and C. Dellach A phase II study of cisplatin and vinorelbine in patients with metastatic breast cancer Ann. Onc., November 1, 2002; 13(11): 1730 - 1736. [Abstract] [Full Text] [PDF]

				C.-J. Tai, W.-S. Wang, J.-H. Liu, C.-C. Yen, F. S. Fan, T.-J. Chiou, and P.-M. Chen Salvage Therapy with Single-agent Paclitaxel by Three-hour Infusion in Metastatic Breast Cancer: an Experience in Taipei Veterans General Hospital Jpn. J. Clin. Oncol., October 1, 2001; 31(10): 477 - 481. [Abstract] [Full Text] [PDF]

				G. V. Kornek, H. Ulrich-Pur, M. Penz, K. Haider;, W. Kwasny, D. Depisch, E. Kovats, F. Lang, B. Schneeweiss, and W. Scheithauer Treatment of Advanced Breast Cancer with Vinorelbine and Docetaxel With or Without Human Granulocyte Colony-Stimulating Factor J. Clin. Oncol., February 1, 2001; 19(3): 621 - 627. [Abstract] [Full Text] [PDF]